NIH Grant

The following reports describe toxicity and pharmacokinetic studies performed under a $3.0 million grant from the National Institutes of Health from 2010-2012/3 supporting systemic use of RGN-352.

REPORTS

Pharmacokinetics, Mass Balance and Tissue Distribution of Radioactivity in Male and Female Sprague-Dawley Rats Administered a Single Intravenous Dose of Tβ4
A 28-Day Study of Thymosin beta 4 (formulated as RGN-352) by Intravenous Injection in Rats with a 2-Week Recovery Period
Effect of Thymosin beta 4 on Cloned hERG Potassium Channels Expressed in Human Embryonic Kidney Cells
A Dosage Range-finding Embryo-fetal Development Study of Thymosin beta 4 (formulated as RGN-352) by Intravenous Injection in Rats
An Embryo-fetal Development Study of Thymosin beta 4 (formulated as RGN-352) Administered by Intravenous Injection in Rats
A Dosage Range-finding Embryo-fetal Development Study of Thymosin beta 4 (formulated as RGN-352) by Intravenous Injection in Rabbits, Including a Preliminary Evaluation in Non-Pregnant Rabbits
An Embryo-fetal Development Study of Thymosin beta 4 (formulated as RGN-352) by Intravenous Injection in Rabbits

print email